Table 5.

Impact of prior murine antibody exposure and antidrug development on omburtamab pharmacokinetics

	No. of patients tested	CSF/blood ratio				t test
		Med	STDEV	Mean	SEM
Dose 1
HAHA neg	16	22.3	32.9	36.3	2.1	0.04*
HAHA pos	11	54.2	239.3	162.6	21.8
No prior Ab	17	19.8	22.9	25.5	1.4	0.02**
Prior Ab	14	55.9	213.1	144.6	15.2
Dose 2
HAHA neg	19	20.4	20.3	25.0	1.1	0.04*
HAHA pos	10	28.1	99.9	76.9	2.8
No prior Ab	15	14.9	15.0	19.9	1.0	0.05**
Prior Ab	14	33.7	85.5	65.4	2.4

Med median, STDEV standard deviation from the mean, SEM standard error of the mean, HAHA human antihuman antigen, Ab antibody

^*t test comparing HAHA-negative vs HAHA-positive patients

^**t test comparing patients with prior mAb exposure vs those without